PT - JOURNAL ARTICLE AU - DANIELLE BOLLER AU - KATHRIN T. DOEPFNER AU - ANGELA DE LAURENTIIS AU - ANA S. GUERREIRO AU - MARIN MARINOV AU - TAREK SHALABY AU - PAUL DEPLEDGE AU - ANTHONY ROBSON AU - NAHID SAGHIR AU - MASAHIKO HAYAKAWA AU - HIROYUKI KAIZAWA AU - TOMONOBU KOIZUMI AU - TAKAHIDE OHISHI AU - SARAH FATTET AU - OLIVIER DELATTRE AU - ANELIA SCHWERI-OLAC AU - KATRIN HÖLAND AU - MICHAEL A. GROTZER AU - KARL FREI AU - OLIVIER SPERTINI AU - MICHAEL D. WATERFIELD AU - ALEXANDRE ARCARO TI - Republication: Targeting PI3KC2β Impairs Proliferation and Survival in Acute Leukemia, Brain Tumours and Neuroendocrine Tumours AID - 10.21873/anticanres.15812 DP - 2022 Jun 01 TA - Anticancer Research PG - 3217--3230 VI - 42 IP - 6 4099 - http://ar.iiarjournals.org/content/42/6/3217.short 4100 - http://ar.iiarjournals.org/content/42/6/3217.full SO - Anticancer Res2022 Jun 01; 42 AB - Background: Eight human catalytic phosphoinositide 3-kinase (PI3K) isoforms exist which are subdivided into three classes. While class I isoforms have been well-studied in cancer, little is known about the functions of class II PI3Ks. Materials and Methods: The expression pattern and functions of the class II PI3KC2β isoform were investigated in a panel of tumour samples and cell lines. Results: Overexpression of PI3KC2β was found in subsets of tumours and cell lines from acute myeloid leukemia (AML), glioblastoma multiforme (GBM), medulloblastoma (MB), neuroblastoma (NB), and small cell lung cancer (SCLC). Specific pharmacological inhibitors of PI3KC2β or RNA interference impaired proliferation of a panel of human cancer cell lines and primary cultures. Inhibition of PI3KC2β also induced apoptosis and sensitised the cancer cells to chemotherapeutic agents. Conclusion: Together, these data show that PI3KC2β contributes to proliferation and survival in AML, brain tumours and neuroendocrine tumours, and may represent a novel target in these malignancies.